ReSynapse Therapeutics is a biotechnology company developing selective multi-target small molecules for treatment-resistant depression. Using systematic computational drug design, we identify compounds that precisely modulate multiple serotonin receptors simultaneously. Our approach combines validated receptor biology with proprietary computational methodologies for better efficacy and safety. The Challenge 20-30% of depression and anxiety patients are treatment-resistant, achieving only 16.7% remission rates with current therapies. Single-target approaches (SSRIs, SNRIs) require 4-6 weeks with significant side effects. Psychedelic-based treatments face regulatory challenges (FDA rejected Lykos' MDMA therapy August 2024). Our Approach We design single molecules that modulate specific combinations of serotonin receptors using mechanism-based computational chemistry. Our platform integrates structural biology, pharmacological understanding, and validated receptor targets to design multi-target compounds systematically. Differentiation • Validated receptor biology (4 specific receptors, 25+ study meta-analysis) eliminates target risk • Proprietary computational methodologies enable systematic multi-target design, impossible with standard software • Selective serotonin targeting avoids dopamine/adrenergic side effects of existing multi-target drugs Current Progress • A combination of 4 receptors was identified and validated for depression • 39 receptor structures systematically analyzed • Various drug candidates identified • In-vitro POC validation is in progress • Non-dilutive grants secured (competitive peer review validation) • IP filing: Q1 2026 | POC validation: Q3-Q4 2026 Stage Seed fundraising for POC validation, lead optimization, and preclinical development pathway. Market Treatment-resistant depression: $1.9B market (2.8M Americans, 11M Europeans). Platform of multi-target drugs is scalable to anxiety, PTSD, other CNS indications.